Literature DB >> 11599597

Temporal indication of marijuana use can be estimated from plasma and urine concentrations of delta9-tetrahydrocannabinol, 11-hydroxy-delta9-tetrahydrocannabinol, and 11-nor-delta9-tetrahydrocannabinol-9-carboxylic acid.

J E Manno1, B R Manno, P M Kemp, D D Alford, I K Abukhalaf, M E McWilliams, F N Hagaman, M J Fitzgerald.   

Abstract

Current technology establishes marijuana use based upon detection of the pharmacologically inactive cannabinoid metabolite (11-nor-delta9-carboxy-tetrahydrocannabinol-9-carboxylic acid, THC-COOH) in urine. No accurate prediction of time of use is possible because THC-COOH has a half-life of 6 days. To determine if a temporal relationship between marijuana use and metabolite excretion patterns could be established, eight healthy user-volunteers (18-35 years old) smoked marijuana cigarettes containing 0% (placebo), 1.77%, and 3.58% delta9-tetrahydrocannabinol (THC). Plasma and urine were collected prior to smoking, 5 min after smoking, and hourly thereafter for 8 h for measurement of cannabinoid concentrations by gas chromatography-mass spectrometry. Mathematical models proposed for determination of recent marijuana use were applied to data from this study and verified the temporal use of marijuana. One subject, who later admitted chronic marijuana use (urine baseline THCCOOH, 529.2 ng/mL; plasma, 75.5 ng/mL), excreted 8beta-dihydroxy-THC, peaking 2 h postsmoking (92.3 ng/mL). Urinary THC, the psychoactive component of marijuana, concentrations peaked 2 h after smoking and declined to assay limit of detection (LOD) (1.5 ng/mL) by 6 h. 11-Hydroxy-delta9-tetrahydrocannabinol (11-OH-THC) and THCCOOH were detectable for the entire 8-h testing period but continued to decrease. Urinary concentrations of THC greater than 1.5 ng/mL suggests marijuana use during the previous 8-h time period.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11599597     DOI: 10.1093/jat/25.7.538

Source DB:  PubMed          Journal:  J Anal Toxicol        ISSN: 0146-4760            Impact factor:   3.367


  17 in total

1.  Identification of recent cannabis use: whole-blood and plasma free and glucuronidated cannabinoid pharmacokinetics following controlled smoked cannabis administration.

Authors:  David M Schwope; Erin L Karschner; David A Gorelick; Marilyn A Huestis
Journal:  Clin Chem       Date:  2011-08-11       Impact factor: 8.327

Review 2.  Cannabis and sport.

Authors:  M Saugy; L Avois; C Saudan; N Robinson; C Giroud; P Mangin; J Dvorak
Journal:  Br J Sports Med       Date:  2006-07       Impact factor: 13.800

Review 3.  Human cannabinoid pharmacokinetics.

Authors:  Marilyn A Huestis
Journal:  Chem Biodivers       Date:  2007-08       Impact factor: 2.408

4.  Pharmacokinetic Characterization of 11-nor-9-carboxy-Δ9-tetrahydrocannabinol in Urine Following Acute Oral Cannabis Ingestion in Healthy Adults.

Authors:  Nicolas J Schlienz; Edward J Cone; Evan S Herrmann; Natalie A Lembeck; John M Mitchell; George E Bigelow; Ronald Flegel; Charles P LoDico; Eugene D Hayes; Ryan Vandrey
Journal:  J Anal Toxicol       Date:  2018-05-01       Impact factor: 3.367

Review 5.  Cannabis in sport: anti-doping perspective.

Authors:  Marilyn A Huestis; Irene Mazzoni; Olivier Rabin
Journal:  Sports Med       Date:  2011-11-01       Impact factor: 11.136

6.  Using Sesame Seed Oil to Preserve and Preconcentrate Cannabinoids for Paper Spray Mass Spectrometry.

Authors:  Brandon Bills; Nicholas Manicke
Journal:  J Am Soc Mass Spectrom       Date:  2020-01-27       Impact factor: 3.109

7.  Cannabis, possible cardiac deaths and the coroner in Ireland.

Authors:  W P Tormey
Journal:  Ir J Med Sci       Date:  2012-01-10       Impact factor: 1.568

Review 8.  Pharmacokinetics and pharmacodynamics of cannabinoids.

Authors:  Franjo Grotenhermen
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

9.  Simultaneous GC-EI-MS determination of Delta9-tetrahydrocannabinol, 11-hydroxy-Delta9-tetrahydrocannabinol, and 11-nor-9-carboxy-Delta9-tetrahydrocannabinol in human urine following tandem enzyme-alkaline hydrolysis.

Authors:  Tsadik T Abraham; Ross H Lowe; Stephane O Pirnay; William D Darwin; Marilyn A Huestis
Journal:  J Anal Toxicol       Date:  2007-10       Impact factor: 3.367

10.  Extended urinary Delta9-tetrahydrocannabinol excretion in chronic cannabis users precludes use as a biomarker of new drug exposure.

Authors:  Ross H Lowe; Tsadik T Abraham; William D Darwin; Ronald Herning; Jean Lud Cadet; Marilyn A Huestis
Journal:  Drug Alcohol Depend       Date:  2009-07-23       Impact factor: 4.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.